Delving into the Latest Updates on Dulaglutide with Synapse

Overview

Basic Info

Drug Type

Fc fusion protein

Synonyms

Dulaglutide (Genetical Recombination), Dulaglutide (genetical recombination) (JAN), Dulaglutide (USAN/INN)

+ [8]

Target

GLP-1R

Action

agonists

Mechanism

GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 2

Inactive Indication

Cardiovascular DiseasesChronic Kidney DiseasesDiabetes Complications+ [5]

Originator Organization

Eli Lilly & Co.

Active Organization

Eli Lilly Nederland BV

Eli Lilly & Co.Eli Lilly Australia Pty Ltd.

Inactive Organization

Lilly Asia Shanghai Representative Office

License Organization

Cipla Ltd.

Sumitomo Pharma Co., Ltd.

Eli Lilly & Co.

Drug Highest PhaseApproved

First Approval Date

United States (18 Sep 2014),

Diabetes Mellitus, Type 2

RegulationPriority Review (China)

Login to view timeline

Structure/Sequence

Sequence Code 51033

Source: *****

Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Start Date03 Feb 2026

Sponsor / Collaborator

The Brigham & Women's Hospital, Inc.

NCT07417618

/ Active, not recruitingNot ApplicableIIT

Comparative Effectiveness of Dulaglutide, Semaglutide, and Tirzepatide in Preventing Cardiovascular Events in Patients With Type 2 Diabetes and Obesity With or Without Atherosclerotic Cardiovascular Disease.

Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Start Date27 Jan 2026

Sponsor / Collaborator

The Brigham & Women's Hospital, Inc.

NCT07309614

/ Not yet recruitingPhase 3

A Multinational, Investigator-initiated, Parallel Group, Randomised, Double-blind, Placebo-controlled Phase 3b Superiority Trial Assessing the Effect of Dupilumab on Inducing Clinical Remission Outcomes in At-risk Type-2 Inflammatory Asthma (HOTHOT)

This study tests whether an asthma medication called dupilumab can help people achieve complete asthma control (called "remission") when given earlier in their disease, before asthma becomes severe. Currently, most people with asthma only receive advanced treatments like biologics after their condition has worsened significantly and caused lung damage. This study explores whether treating high-risk patients earlier could prevent asthma attacks and lung function decline, potentially achieving remission before permanent damage occurs. The study is looking for adults aged 18-79 with moderate asthma who have had at least one asthma attack requiring steroid pills in the past 2 years, use medium or high-dose inhaled steroids regularly, have high levels of inflammation markers in their blood and breath tests, but don't yet meet criteria for severe asthma requiring biologic therapy. Participants receive either dupilumab or placebo injections every 2 weeks for one year, alongside their regular asthma medications. They attend clinic visits every 3 months for breathing tests, questionnaires, and safety monitoring. Neither participants nor doctors know who receives the real medication until the study ends. The goal is to learn whether early treatment with dupilumab helps more people achieve complete asthma control compared to standard care alone, potentially changing how asthma is treated from "waiting until severe" to "preventing severe disease." The study runs in Canada, the United Kingdom, and Australia, involving 150 participants

Start Date01 Jan 2026

Sponsor / Collaborator

University of Sherbrooke

[+5]

100 Clinical Results associated with Dulaglutide

Login to view more data

100 Translational Medicine associated with Dulaglutide

Login to view more data

100 Patents (Medical) associated with Dulaglutide

Login to view more data

1,277

Literatures (Medical) associated with Dulaglutide

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Calculating cost per event avoided using a composite number needed to treat

Article

Author: Wang, Julia ; Bhavsar, Jigish ; Toliver, Joshua ; Sullivan, Sean D.

OBJECTIVE:

Number needed to treat (NNT) and cost per event avoided (CPEA) are measures used to represent the clinical and economic value of chronic treatments and are commonly calculated based on primary endpoints from trials. This approach, although widely used, does not reflect the complete value of a treatment, as it does not consider outcomes beyond the primary endpoints. This research aims to overcome this limitation by developing multiple composite NNTs to derive the CPEA to estimate a total value of semaglutide and dulaglutide in people with established cardiovascular disease.

METHODS:

Two cardiovascular outcomes trials were selected, SELECT (NCT03574597, semaglutide 2.4 mg) and REWIND (NCT01394952, dulaglutide 1.5 mg). NNT was calculated as NNT = 1/ARR where ARR = control event rate - experimental event rate. NNT was estimated for 3-point major adverse cardiovascular events (MACE-3; primary endpoint of the trials), 5-point MACE (MACE-5), and cardiovascular-kidney-metabolic events (CKM). CPEA of MACE-3, MACE-5, and CKM was calculated as NNT*duration of mean follow-up (semaglutide) or duration of median follow-up (dulaglutide)*estimated net price.

RESULTS:

The NNT decreased as the number of outcomes in the composite endpoint increased, where NNT_MACE-3, NNT_MACE-5, and NNT_CKM were 67, 49, and 8 for semaglutide, and 72, 64, and 23 for dulaglutide, respectively. Similarly, the CPEA decreased as the number of outcomes in the composite endpoint increased, where the CPEA for MACE-3, MACE-5 and CKM calculations were $1,662,001, $1,232,417, and $190,387 for semaglutide and $1,884,013, $1,670,366, and $607,886 for dulaglutide.

CONCLUSIONS:

This research illustrates the limitations of using a NNT focused only on the primary endpoint, as it does not capture the total benefit of the treatment. When considering the value of treatments through NNT or CPEA analyses, a composite endpoint capturing broader benefit should be utilized.

01 Apr 2026·JOURNAL OF PSYCHIATRIC RESEARCH

Retrospective chart review on psychiatric manifestations of GLP-1 agonist usage

Article

Author: Buciuc, Adela-Georgiana ; Kumbkarni, Nayha ; Sa, Brianna ; Maristany, Anthony ; Oldak, Sean ; Padilla, Vanessa ; Subramaniam, Ashwin ; Lange, Rachel

BACKGROUND:

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes mellitus and obesity. Beyond metabolic effects, GLP-1 signaling influences central pathways involved in mood, reward, and stress regulation, raising interest in possible psychiatric implications.

METHODS:

We conducted a retrospective chart review of adults (≥18 years) prescribed GLP-1 RAs at a private university hospital between January 2021 and April 2024. Demographic, medication, and psychiatric data were extracted from electronic health records. Primary outcomes included stability, improvement, worsening, or new onset of psychiatric disorders during treatment.

RESULTS:

Among 226 patients (mean age 53.5 years; 66.8 % female; mean BMI 33.6 kg/m²), semaglutide was most frequently prescribed (73 %). The mean treatment duration was 20.2 months, with an average 6.7 % weight loss. Major depressive disorder (MDD) and generalized anxiety disorder (GAD) were most prevalent (68.6 % and 65.9 % of patients, respectively). Most remained stable (MDD: 73.6 %; GAD: 78.5 %). New-onset MDD occurred in 9.0 % and GAD in 8.7 % of affected patients, with mean latencies of 15.8 and 16.8 months, respectively. Adjustment disorder, ADHD, and insomnia also emerged in a subset, with ADHD showing the shortest latency to onset (7.8 months). Rare new-onset alcohol use disorder, trichotillomania, and opioid use disorder were observed.

CONCLUSIONS:

GLP-1 RAs appear psychiatrically well-tolerated for most patients, though new-onset or worsening symptoms occur in a minority, underscoring the need for monitoring, particularly in high-risk populations. Prospective studies are warranted to clarify causality, mechanisms, and potential therapeutic roles in psychiatric care.

01 Mar 2026·JOURNAL OF DIABETES AND ITS COMPLICATIONS

Effects of GLP-1 receptor agonists on vascular dementia: a systematic review and meta-analysis

Review

Author: Panagiotopoulos, Evangelos ; Theodorou, Aikaterini ; Ziemann, Ulf ; Peppa, Melpomeni ; Stefanou, Maria-Ioanna ; Giannopoulos, Sotirios ; Paraskevas, Georgios P ; Sharma, Vijay K ; Athanasaki, Athanasia ; Papadopoulou, Marianna ; Lambadiari, Vaia ; Siasos, Gerasimos ; Tsivgoulis, Georgios ; Tentolouris, Anastasios ; Mengel, Annerose

BACKGROUND AND AIMS:

Vascular dementia (VaD) is strongly associated with type 2 diabetes (T2DM), overweight, and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce cardiovascular risk and exhibit neuroprotective properties, yet their effects in incident VaD remain uncertain. This study evaluated whether GLP-1 RAs have preventive potential for VaD in adults with T2DM, overweight, or obesity.

METHODS:

A systematic review and meta-analysis of randomized-controlled clinical trials (RCTs) was conducted to estimate the risk of incident VaD among patients with T2DM or overweight/obesity treated with GLP-1 RAs versus placebo. Data were pooled using a random-effects model, with outcomes expressed as risk ratios (RRs) and 95% confidence intervals (CIs). Subgroup analysis was performed after stratification by population type (T2DM vs. overweight/obesity), and meta-regression assessed the association between RCT duration and effect size.

RESULTS:

Seven RCTs (six in T2DM, one in overweight/obesity) comprising 61,610 participants were included. GLP-1 RA treatment was not associated with a statistically significant difference in VaD incidence (RR: 0.50; 95% CI: 0.19-1.32; I² = 0%). Subgroup analysis revealed no significant between-group differences (p for subgroups = 0.612), although numerically lower VaD rates were observed in the T2DM subgroup (RR: 0.38; 95% CI: 0.13-1.11). Meta-regression did not demonstrate a significant association between follow-up duration and treatment effect (β = -0.291; SE = 0.212; 95% CI: -0.843 to 0.262; p = 0.229).

CONCLUSIONS:

The pooled evidence did not confirm a statistically significant reduction in VaD risk with GLP-1 RA therapy. Numerically lower VaD incidence in T2DM populations warrants further investigation in adequately powered and systematically adjudicated trials.

505

News (Medical) associated with Dulaglutide

6 hours ago

·www.prnewswire.com

Parker Waichman LLP's Jason Goldstein Appointed to Co-Chair of Plaintiffs' Executive Committee and Federal-State Court Liaison in the GLP-1 NAION Litigation

Judge Karen Marston of the Eastern District of Pennsylvania issued the Order on February 23, 2026 Appointing Jason Goldstein to Co-Chair of the Plaintiffs' Executive Committee and Federal-State Court Liaison in MDL 3163. KEY HIGHLIGHTS Jason Goldstein, Senior Litigation Counsel at Parker Waichman LLP, appointed to Co-Chair of Plaintiffs' Executive Committee and Federal-State Court Liaison of MDL 3163 in the EDPA by Judge Karen Marston. MDL 3163 involves claims by Plaintiffs that GLP-1 RAs such as Ozempic, Wegovy, Mounjaro and Zepbound, caused NAION, a debilitating eye injury. NAION causes sudden partial or complete permanent blindness in one or both eyes. PORT WASHINGTON, N.Y., Feb. 25, 2026 /PRNewswire/ -- Parker Waichman LLP is proud to announce that Jason Goldstein, Senior Litigation Counsel at the firm, has been appointed to Co-Chair of Plaintiffs' Executive Committee and Federal–State Court Liaison in MDL 3163 by the Honorable Karen Marston, United States District Judge for the Eastern District of Pennsylvania. MDL 3163 centralizes federal cases involving allegations that certain GLP-1 receptor agonist medications are associated with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)—a serious and often irreversible condition that results in optic nerve damage and permanent vision loss. The litigation focuses on widely prescribed GLP-1 drugs, including: Ozempic Wegovy Mounjaro Zepbound These medications, used for treatment of type 2 diabetes and weight management, have been alleged in filed cases to increase the risk of sudden optic nerve ischemia resulting in partial or complete vision loss. Judge Marston's appointment of Mr. Goldstein reflects the Court's confidence in his experience in complex pharmaceutical litigation and his ability to coordinate efficiently between federal and state proceedings nationwide. As a Co-Chair of Plaintiffs' Executive Committee and Federal–State Liaison Counsel, Mr. Goldstein will play a critical leadership role in facilitating communication among courts, overseeing coordinated discovery efforts, and advancing claims brought by individuals who suffered catastrophic vision injuries. "NAION is a devastating diagnosis that frequently occurs without warning and can permanently alter a person's independence, livelihood, and quality of life," said Jason Goldstein. "I am honored by Judge Marston's appointment and committed to working collaboratively with the Court and counsel to ensure these GLP-1 NAION cases are prosecuted efficiently, transparently, and with the seriousness they deserve." NAION occurs when blood flow to the optic nerve is compromised, often leading to sudden and irreversible blindness in one eye. Plaintiffs in MDL 3163 allege that the manufacturers of GLP-1 medications failed to adequately warn patients and prescribing physicians of the potential risk of optic nerve injury and failed to properly investigate or disclose this association. Parker Waichman LLP represents individuals nationwide who have suffered serious injuries allegedly linked to GLP-1 medications. The firm remains committed to holding manufacturers accountable and ensuring that injured patients receive the justice they deserve. Individuals diagnosed with NAION after taking Ozempic, Wegovy, Mounjaro, Zepbound, or other GLP-1 medications are encouraged to seek legal guidance regarding their rights. Free Case Review for Affected Individuals If you or a loved one were treated with a GLP-1 RA, including, but not limited to, Ozempic, Wegovy, Mounjaro and Zepbound, and developed NAION or associated symptoms such as eye stroke, sudden partial or complete blindness in one or both eyes, or significant vision loss affecting your quality of life, you may have a legal claim. Parker Waichman LLP is offering free, no-obligation case evaluations to help victims understand their rights and pursue justice. Contact Parker Waichman LLP Today For a free consultation, call 1-800-YOUR-LAWYER (1-800-968-7529) or visit YourLawyer.com to learn more about your legal options and how to protect your rights. About Parker Waichman LLP Parker Waichman LLP is a nationally recognized law firm dedicated to fighting for victims of defective drugs, dangerous products, accidents, and corporate negligence. With a proven track record of holding multi-national corporations accountable, the firm has secured billions in settlements and verdicts for injured clients. Media Contact: Jason Goldstein Phone: 516-466-6500 Email: [email protected] SOURCE Parker Waichman LLP 21% more press release views with Request a Demo

Executive Change

18 Feb 2026

·www.drugs.com

Risk for Nonscarring Hair Loss Increased in Association With GLP-1 Receptor Agonist Use

WEDNESDAY, Feb. 18, 2026 -- The risk for nonscarring hair loss (NSHL) is increased in association with glucagon-like peptide-1 receptor agonist (GLP-1 RA) use, according to a study published online Feb. 9 in the Journal of the American Academy of Dermatology . Savanna I. Vidal, from the George Washington University School of Medicine and Health Sciences in the Washington, D.C., and colleagues used the TriNetX U.S. Collaborative Network to examine the incidence and risk for NSHL in adults (aged 18 to 89 years) and adolescents (aged 12 to 17 years) treated with GLP-1 RA versus matched controls from 2014 to 2024. Data were included for 547,993 matched adult GLP-1 RA users and controls. The researchers found that for both GLP-1 RA users and controls, there was an increase in the incidence of NSHL, telogen effluvium (TE), androgenetic alopecia (AGA), and alopecia areata between 2014 and 2024. Incidence curves for overall NSHL began to diverge around 2019, with consistently higher rates for GLP-1 RA users by 2023 to 2024. For TE and AGA, the rates remained similar until 2021 to 2022, followed by a sharper increase among GLP-1 RA users. GLP-1 RAs were linked to a significantly higher risk for AGA and NSHL at six months (adjusted odds ratios, 1.62 and 1.26, respectively). Risks increased for TE, AGA, and NSHL at 12 months (adjusted odds ratios, 1.76, 1.64, and 1.40, respectively). "Awareness of alopecia risk in patients on GLP-1 RAs is critical for early detection, anticipatory guidance, and multidisciplinary care," the authors write. Abstract/Full Text

Clinical Result

10 Feb 2026

·www.drugs.com

Sodium-Glucose Cotransporter 2 Inhibitors Tied to Lower Use of Gout Medications

TUESDAY, Feb. 10, 2026 -- For patients with gout and type 2 diabetes , sodium-glucose cotransporter 2 inhibitors (SGLT2is) may reduce the need for gout-related medication, according to a study published online Jan. 30 in Diabetes Care . Natalie McCormick, Ph.D., from Massachusetts General Hospital in Boston, and colleagues compared rates of allopurinol initiation and use of anti-inflammatories (high-dose glucocorticoids, nonsteroidal anti-inflammatory drugs [NSAIDs], colchicine) and diuretics (prototypic serum urate-raising medication) among 26,739 adults with gout and type 2 diabetes using SGLT2is versus dipeptidyl peptidase 4 inhibitors (DPP-4is) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs). The researchers found that allopurinol initiation was lower among SGLT2i initiators than DPP-4i users (hazard ratio, 0.62). Among those using diuretics at baseline, associations were stronger and persisted when comparing SGLT2i to GLP-1 RAs and accounting for serum urate and body mass index. SGLT2i use was also associated with lower rates of high-dose glucocorticoid (rate ratio [RR], 0.78), NSAID (RR, 0.85), colchicine (RR, 0.87), and diuretic dispensing (RR, 0.87). "For patients with gout and type 2 diabetes, SGLT2is may reduce gout-related medication use, which could, in turn, reduce exposure to the harmful cardiovascular-kidney-metabolic effects of NSAIDs and glucocorticoids in this high-risk population," the authors write. Two authors disclosed ties to the pharmaceutical and biotechnology industries. Abstract/Full Text (subscription or payment may be required)

Clinical Result

100 Deals associated with Dulaglutide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09889	Dulaglutide	A10BJ05	DB09045

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	United States	Eli Lilly & Co.	18 Sep 2014

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypoglycemia	Phase 3	Japan	Eli Lilly & Co.	13 Apr 2021
Chronic Kidney Diseases	Phase 3	Spain	Eli Lilly & Co.	05 Sep 2012
Diabetes Complications	Phase 3	Sweden	Eli Lilly & Co.	06 Oct 2011
Cardiovascular Diseases	Phase 3	United States	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Argentina	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Australia	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Brazil	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Bulgaria	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Canada	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Chile	Eli Lilly & Co.	22 Jul 2011

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03204396 (Pubmed \| Eur J Prev Cardiol)	Phase 2	Smoking Cessation	255	Dulaglutide 1.5mg	supqrhhiiq(usjcdsngii) = systolic blood pressure was stable over the period of 52 weeks after smoking cessation hhlfygqgbs (lyszoxympv )	-	10 Oct 2025
NCT05680129 (EECOH-2, Literature) Manual	Phase 3	Diabetes Mellitus, Type 2	621	ecnoglutide 0.6 mg	xmrsvulcor(ppldjetzes) = noswngwyaj ugjmeixevl (smkimqeoxv ) View more	Positive	22 Aug 2025
				ecnoglutide 1.2 mg	xmrsvulcor(ppldjetzes) = imtqagwtdf ugjmeixevl (smkimqeoxv ) View more
NCT04255433 (SURPASS-CVOT, PRNewswire) Manual	Phase 3	Diabetes Mellitus, Type 2 \| Atherosclerosis	13,299	Mounjaro (tirzepatide)	mutfcsolni(xtefwzxwge): HR = 0.92 (95.3% CI, 0.83 - 1.01) Met View more	Non-inferior	31 Jul 2025
				Trulicity (dulaglutide)
NCT04255433 (SURPASS-CVOT, ADA 12025 \| ADA 22025) Manual	Phase 3	Diabetes Mellitus, Type 2	15,775	Tirzepatide (overall cohort)	sfzmubukhj(mgvcslqujt) = ailnlhftqv pskzuvoazc (vljqaoaoci )	Positive	20 Jun 2025
				Dulaglutide (overall cohort)	sfzmubukhj(mgvcslqujt) = pwfymdtkte pskzuvoazc (vljqaoaoci )
ADA2025	Not Applicable	Diabetes Mellitus, Type 2	173	Dulaglutide	spxsmseyzl(gwdvwgrftj) = Individual GLP-1RA were associated with an increased risk of GI adverse events compared with SGLT-2i. cqqjkftwfa (kxfosjhaca ) View more	Positive	20 Jun 2025
				Semaglutide
NCT05659537 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	212	Dulaglutide	wifdkacveo = hrttkcikdl odqnfrqwfo (uawwsgemkd, huqcfwffpl - mtjtonxssb) View more	-	05 Feb 2025
ASCO_GI2025	Not Applicable	Advanced biliary tract cancer	50	Durvalumab plus gemcitabine and cisplatin	dxvyfhcqyp(vembzwhxtj) = Most AEs were related to chemotherapy, there were 10% immune related AEs pqzwpvcfej (dylimqntgt )	Positive	23 Jan 2025
TOPAZ-1 (ASCO_GI2025)	Not Applicable	Advanced biliary tract cancer	1,099	Durvalumab plus chemotherapy	xwwbvfddik(tklhkltrny) = wunfriqhhm oacntrwiyb (fslomkzrgw )	Positive	23 Jan 2025
				Chemotherapy only	xwwbvfddik(tklhkltrny) = cehmwlljhb oacntrwiyb (fslomkzrgw )
ASCO_GI2025	Not Applicable	Advanced biliary tract cancer First line	-	Durvalumab + Lenvatinib + Gemcitabine-based chemotherapy	odgmgnbzkh(ywejkybjcn) = All patients experienced adverse events (AEs), addition of lenvatinib does not increase the risk of AEs tfvxikqrgz (zmddfcaxsl )	Positive	23 Jan 2025
				Durvalumab + Gemcitabine-based chemotherapy
ACTRN12623000223639 (ASCO_GI2025)	Not Applicable	Advanced Pancreatic Ductal Adenocarcinoma	30	Gemcitabine + Nab-paclitaxel + LSTA-1 + Durvalumab	aldkygqzdm(gfmlxsuukt) = xezjkfgpec pifkailaho (ctmlnocnkc )	Positive	23 Jan 2025

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Dulaglutide

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation